Analysts took action on healthcare stocks on Thursday, May 24.
Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals, Inc. (APLS, Financial) with an ‘Overweight’ rating. The firm has set a price target on Apellis Pharmaceuticals of $52 per share. That is a 157% growth from the current market valuation of $20.23. The stock closed 2.9% up on May 24 and the market capitalization is $1.132 billion.
Cantor Fitzgerald’s estimate will drag the average target price up to about $38.6 per share of Apellis Pharmaceuticals from a previous mean value of $35.25 per share.
Currently the stock in Apellis Pharmaceuticals has a recommendation rating of 2 out of 5. As of May, there are three analysts who recommend buying shares of the company.
According to GuruFocus, the stock in Apellis Pharmaceuticals has a price-book ratio of 8.41 times versus an industry median of 4.51, and enterprise value to earnings before interest taxed depreciation and amortization (EV-to-EBITDA) ratio of -17.80 versus an industry median of 21.70.
The stock lost 7% this year. The 52-week range is from $12.45 to $32 per share.
SunTrust Banks Inc. (STI) started covering the stock in UniQure (QURE, Financial) with a ‘Buy’ rating. The U.S. bank holding company set a price target of $48 per share of UniQure.
Compared to the current share price of $34.84, the price target represents a 37.8% increase. The estimate of SunTrust will push the average target price up to $44 from a current $43.2 per share.
The stock has a recommendation rating of 1.7 out of 5. As of May, five analysts suggested buying shares of UniQure.
UniQure has a market capitalization of $1.29 billion, a price-book ratio of 11.04 versus an industry median of 4.51, and a price-sales ratio of 73.81.
The stock has climbed 73% this year. The 52-week range is from $4.90 to $35.75 per share.
Craig Hallum gave Accelerate Diagnostics (AXDX, Financial) a $25 price target and ‘Hold’ rating. The price target represents a 22.2% growth from the current share price of $20.45. The estimate will cause a decrease of 50 cents in the average target price to $26 per share.
As of May 2018, four analysts recommend buying shares of the company. The recommendation rating is 2 out of 5.
The stock is trading at $20.45 on the Nasdaq Composite and has fallen 26% so far this year. The 52-week range per share is from $16.75 to $30.45.
Accelerate Diagnostics has a market capitalization of $1.1 billion, a price-book ratio of 10.73 versus an industry median of 4.02, and a price-sales ratio of 255.65 versus an industry median of 3.81.
Accelerate Diagnostics is presumably trading above the Peter Lynch earnings line with and without NRI:
Goldman Sachs has removed AbbVie (ABBV, Financial) from its conviction list. However, the ‘Buy’ rating is maintained.
AbbVie has an average target price of $115.90 per share and a recommendation rating of 2.3 out of a total of 5.
The U.S. healthcare stock has a market capitalization of $163.67 billion, a price-book ratio of 46.05 versus an industry median of 2.96, a price-sales ratio of 5.57 versus an industry median of 3.25 and a price-earnings ratio of 25.96 versus an industry median of 26.44.
AbbVie has climbed 5% to $103.14 so far this year and is trading at about $22.72 per share below the 52-week high of $125.86. The 52-week low is $65.67.
The forward price-earnings ratio is 13.59 versus an industry median of 20. When the forward price-earnings ratio is multiplied by the earnings per share of $7.77 – as forecasted by analysts for full fiscal 2018 – it yields a value of $105.6 per share. For full fiscal 2019, analysts expect AbbVie will report an earnings per share of $8.89.
AbbVie has a forward annual dividend of $3.84 for a yield of 3.73%.
According to the chart powered by GuruFocus, the share price of AbbVie is currently above the Peter Lynch Earnings Line (P/E = 15) and the Price at Med P/E without NRI (P/E = 19.3):
Wedbush downgraded shares of Karyopharm Therapeutics (KPTI, Financial) to a ‘Neutral’ rating with a price target of $19 per share. That is a 9.6% growth from the current market valuation of $17.34 per share. The stock tumbled 9% on May 24 and the market capitalization is $1.044 billion.
Wedbush’s estimate will drag the average target price down to about $22 per share from a previous $22.27 per share of Karyopharm Therapeutics.
Currently, the stock in Karyopharm Therapeutics has a recommendation rating of 1.7 out of 5. As of May 2018, there are10 analysts who recommend buying shares of the company. One analyst predicts an underperforming stock within the following 52-weeks of trading.
According to GuruFocus, the stock in Karyopharm Therapeutics has a price-book ratio of 9.06 times versus an industry median of 2.96, a price-sales ratio of 74.43 times versus an industry median of 3.25 times, and an enterprise value to earnings before interest taxed depreciation and amortization (EV-to-EBITDA) ratio of -6.6 versus an industry median of 16.59.
The stock gained 75% this year. The 52-week range is from $7.48 to $20.39 per share.
According to GuruFocus’ chart, the share price of Karyopharm Therapeutics ($17.3) is below the Peter Lynch Earnings Line (P/E = 15) of $28.5 and the Price at Med P/E without NRI (P/E = 20.2) of $38.4:
(Disclosure: I have no positions in any security mentioned in this article.)
